Literature DB >> 31587263

Summative Effects of Vascular Risk Factors on the Progression of Alzheimer Disease.

Wei-Ju Lee1,2,3,4,5, Yi-Chu Liao2,6, Yen-Feng Wang2,5,7, Yung-Shuan Lin2,7, Shuu-Jiun Wang2,5,7, Jong-Ling Fuh2,5,7.   

Abstract

OBJECTIVES: To investigate the summative effects of vascular risk factors (VRFs) on the progression of Alzheimer disease (AD).
DESIGN: Longitudinal follow-up cohort study.
SETTING: AD patients from two teaching hospitals in Taiwan with 3-year follow-ups. PARTICIPANTS: A total of 330 AD patients with a mean age of 80.7 years, a mean Mini-Mental State Examination (MMSE) score 18.7, and a mean Clinical Dementia Rating Sum of Boxes (CDRSB) score of 6.9. MEASUREMENTS: All patients completed a clinically functional assessment and a neuropsychological test battery at baseline and yearly follow-ups. The VRF burden was combined into a summative VRF index at baseline (ie, having one, two, or more VRFs); VRFs included coronary heart disease, cardiac arrhythmia, hypertension, cerebrovascular disease, diabetes mellitus, obesity, smoking, and physical inactivity. The generalized estimating equation (GEE) method was used to analyze the correlations between the VRFs and longitudinal MMSE and CDRSB changes.
RESULTS: The results of the GEE adjusted for age, years of education, sex, disease duration, baseline MMSE score, time, apolipoprotein E (APOE) ε4 carrier status, use of medications (acetylcholinesterase inhibitors or N-methyl-D-aspartate receptor antagonists), and hospitalization rates and showed that patients with more than three VRFs had more rapid cognitive decline than patients without VRFs (MMSE, P = .02; CDRSB, P = .001) as well as patients with three or fewer VRFs (MMSE, P = .009; CDRSB, P = .02). Subsequent analyses of APOE ε4 carriers with more than three VRFs also showed their more rapid cognitive decline compared with patients without VRFs (MMSE, P = .02; CDRSB, P = .001) and patients with three or fewer VRFs (MMSE, P = .009; CDRSB, P = .02), but no significant difference was found in APOE ε4 noncarriers.
CONCLUSION: Multiple VRFs have summative effects on the progression of AD, especially in APOE ε4 carriers. J Am Geriatr Soc 68:129-136, 2019.
© 2019 The American Geriatrics Society.

Entities:  

Keywords:  Alzheimer disease; apolipoprotein E; cognitive declinevascular risk factors

Year:  2019        PMID: 31587263     DOI: 10.1111/jgs.16181

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  8 in total

1.  Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer's Disease.

Authors:  Ming Zhang; Wei Han; Yuhao Xu; Dapeng Li; Qun Xue
Journal:  Neuropsychiatr Dis Treat       Date:  2021-01-29       Impact factor: 2.570

Review 2.  Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

Authors:  Geetika Nehra; Bjoern Bauer; Anika M S Hartz
Journal:  Pharmacol Ther       Date:  2022-01-30       Impact factor: 13.400

3.  Dl-3-n-butylphthalide regulates cholinergic dysfunction in chronic cerebral hypoperfusion rats.

Authors:  Yanan Sun; Zilong Zhao; Qi Li; Chunyang Wang; Xintong Ge; Xing Wang; Gang Wang; Yu Qin
Journal:  J Int Med Res       Date:  2020-07       Impact factor: 1.671

4.  Cortical atrophy mediates the accumulating effects of vascular risk factors on cognitive decline in the Alzheimer's disease spectrum.

Authors:  Qing Wang; Cancan He; Yao Zhu; Qianqian Zhang; Zhijun Zhang; Chunming Xie
Journal:  Aging (Albany NY)       Date:  2020-07-29       Impact factor: 5.682

5.  Frequency of missed or delayed diagnosis in dementia is associated with neighborhood socioeconomic status.

Authors:  Ellen Holm; Katja Kemp Jacobsen; Thea Bang de Lony; Maurice Lembeck; Hanne Pedersen; Charlotte Andersson; Peter Johannsen; Terese Sara Høj Jørgensen; Christian Torp-Pedersen
Journal:  Alzheimers Dement (N Y)       Date:  2022-03-24

6.  Absence of an Association between Macular Degeneration and Young-Onset Dementia.

Authors:  Tung-Mei Tammy Kuang; Sudha Xirasagar; Wei-Yun Lee; Yen-Fu Cheng; Nai-Wen Kuo; Herng-Ching Lin
Journal:  J Pers Med       Date:  2022-02-16

7.  Transcranial magnetic stimulation treatment in Alzheimer's disease: a meta-analysis of its efficacy as a function of protocol characteristics and degree of personalization.

Authors:  Arianna Menardi; Lisa Dotti; Ettore Ambrosini; Antonino Vallesi
Journal:  J Neurol       Date:  2022-07-04       Impact factor: 6.682

8.  The relationship between urinary Alzheimer-associated neuronal thread protein and blood biochemical indicators in the general population.

Authors:  Yuxia Li; Shaochen Guan; He Jin; Hongjun Liu; Meimei Kang; Xiaozhen Wang; Can Sheng; Yu Sun; Xuanyu Li; Xianghua Fang; Rong Wang
Journal:  Aging (Albany NY)       Date:  2020-07-31       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.